Novel mechanism of rapamycin in GVHD: Increase in interstitial regulatory T cells

13Citations
Citations of this article
15Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Rapamycin (RAPA) is an immunosuppressive drug that prevents and treats graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplant (HCT). One possible mechanism for its efficacy is induction of tolerance, through increased number or enhanced survival of regulatory T cells. In our experiments, B10.D2 BM and splenocytes were injected into lethally irradiated BALB/cJ recipients. The mice received i.p. injections of either RAPA or vehicle control on days 1-28. There was a significant survival advantage in RAPA-treated mice. Evaluation of the skin biopsies showed a dense cellular infiltrate in RAPA-treated mice. Further characterization of these cells revealed a higher percentage of regulatory T cells characterized by FoxP3-positive cells in high-dose RAPA-treated mice as compared with controls on day 30. This effect appears to be dose dependent. When peripheral blood analysis for FoxP3-positive cells was performed, there was no significant difference observed in the RAPA-treated mice as compared with control mice. These data show a novel mechanism of rapamycin in GVHD, accumulation of regulatory T cells in the GVHD target tissue: the skin. © 2010 Macmillan Publishers Limited All rights reserved.

Cite

CITATION STYLE

APA

Palmer, J. M., Chen, B. J., Deoliveira, D., Le, N. D., & Chao, N. J. (2010). Novel mechanism of rapamycin in GVHD: Increase in interstitial regulatory T cells. Bone Marrow Transplantation, 45(2), 379–384. https://doi.org/10.1038/bmt.2009.140

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free